Clinical trial · no report yet · Phase 2
SAVANNAH
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- NCT03778229 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Carcinoma
- Interventions
- osimertinib; savolitinib; placebo
- Arms
- osimertinib + savolitinib · Experimental
- placebo + savolitinib · Placebo comparator
- Enrollment
- 367
- Primary outcomes
- Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set
- Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set
- Sponsor
- AstraZeneca with Hutchison Medipharma Limited
- Start
- Jan 9, 2019
- Primary completion
- Aug 23, 2024
- Results posted
- Yes
- Registry record
- NCT03778229 · updated Apr 23, 2026
Publications
linked from the registry- de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeno J, Baldotto C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn MJ. A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib. Future Oncol. 2026 Jul;22(17):2013-2025. doi: 10.1080/14796694.2026.2692029. Epub 2026 Jul 16. PubMed 42460617
- Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW. Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. Clin Lung Cancer. 2026 Jan;27(1):38-46. doi: 10.1016/j.cllc.2025.10.018. Epub 2025 Oct 22. PubMed 41308232
- Schmid S, Fruh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3. No abstract available. PubMed 32027845